Taysha Gene Therapies Q1 EPS $(0.10) Beats $(0.11) Estimate, Sales $3.41M Beat $2.56M Estimate
Taysha Gene Therapies Q1 EPS $(0.10) Beats $(0.11) Estimate, Sales $3.41M Beat $2.56M Estimate
Taysha Gene Therapies第一季度每股收益美元（0.10）超過預期（0.11）美元，銷售額341萬美元超過256萬美元的預期
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $3.41 million which beat the analyst consensus estimate of $2.56 million by 33.24 percent. This is a 27.52 percent decrease over sales of $4.71 million the same period last year.
Taysha Gene Therapies（納斯達克股票代碼：TSHA）公佈的季度虧損爲每股0.10美元，比分析師普遍預期的0.11美元（0.11美元）高出9.09％。這比去年同期每股虧損0.28美元（0.28美元）增長了64.29％。該公司公佈的季度銷售額爲341萬美元，比分析師普遍預期的256萬美元高出33.24％。這比去年同期的471萬美元銷售額下降了27.52％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。